Search Results - Arun Azad

Refine Results
  1. 1
    Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?

    Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? by Ramin Alipour, Arun Azad, Michael S. Hofman

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer

    Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer by Louise Kostos, James Buteau, Michael S. Hofman, Arun Azad

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab

    Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab by Hui Gan, Arun Azad, Lawrence Cher, P. L.R. Mitchell

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Radiotherapy and immunotherapy: a synergistic effect in cancer care

    Radiotherapy and immunotherapy: a synergistic effect in cancer care by Guy‐Anne Turgeon, Andrew Weickhardt, Arun Azad, Benjamin Solomon, Shankar Siva

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

    PD-L1 is highly expressed in Enzalutamide resistant prostate cancer by Jennifer L. Bishop, Alexander Sio, Arkhjamil Angeles, Morgan E. Roberts, Arun Azad, Kim N., Amina Zoubeidi

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer

    Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer by Omattage Mahasha Perera, Patrick B. Thomas, Gail P. Risbridger, Renea A. Taylor, Arun Azad, Michael S. Hofman, Elizabeth D. Williams, Ian Vela

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

    TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer by Neeraj Agarwal, Fred Saad, Arun Azad, Joaquı́n Mateo, Nobuaki Matsubara, Neal D. Shore, Jayeta Chakrabarti, Hsiang-Chun Chen, Silvana Lanzalone, Alexander Niyazov, Karim Fizazi

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells

    Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells by Arun Azad, Susan Jackson, Carleen Cullinane, Anthony Natoli, Paul M. Neilsen, David F. Callen, Sauveur-Michel Maira, Wolfgang Hackl, Grant A. McArthur, Benjamin Solomon

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Modern paradigms for prostate cancer detection and management

    Modern paradigms for prostate cancer detection and management by Isabella SC Williams, Aoife McVey, Sachin Perera, J O’Brien, Louise Kostos, Kenneth Chen, Shankar Siva, Arun Azad, Declan G. Murphy, Veeru Kasivisvanathan, Nathan Lawrentschuk, Mark Frydenberg

    Published 2022
    Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer

    Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer by Arun Azad, Louise Kostos, Neeraj Agarwal, Gerhardt Attard, Ian D. Davis, Tanya B. Dorff, Silke Gillessen, Chris Parker, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Karim Fizazi

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late

    Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late by Maarten J. IJzerman, Jasper de Boer, Arun Azad, Koen Degeling, Joel Geoghegan, Chelsee Hewitt, Frédéric Hollande, Belinda Lee, Yat Ho To, Richard W. Tothill, Gavin Wright, Jeanne Tie, Sarah‐Jane Dawson

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

    AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol) by Louise Kostos, James Buteau, Theresa Yeung, Juliana Di Iulio, Jing Xie, Anthony Cardin, Kwang Chin, Brittany Emmerson, Katie L. Owen, Belinda S. Parker, Heidi Fettke, Luc Furic, Arun Azad, Michael S. Hofman

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design by Neeraj Agarwal, Arun Azad, Neal D. Shore, Joan Carles, André P. Fay, Curtis Dunshee, Lawrence I. Karsh, M. Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

    Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prost... by Neeraj Agarwal, Arun Azad, Neal D. Shore, Joan Carles, André P. Fay, Curtis Dunshee, Lawrence I. Karsh, M. Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer

    Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherap... by Andrew Weickhardt, Timothy Price, Geoff Chong, Val Gebski, Nick Pavlakis, Terrance G. Johns, Arun Azad, Effie Skrinos, Kate Fluck, Alexander Dobrovic, Renato Salemi, Andrew M. Scott, John M. Mariadason, Niall C. Tebbutt

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    TheraP: a randomized phase 2 trial of <sup>177</sup>Lu‐<scp>PSMA</scp>‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol <scp>ANZUP</scp> 1603)

    TheraP: a randomized phase 2 trial of <sup>177</sup>Lu‐<scp>PSMA</scp>‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clin... by Michael S. Hofman, Louise Emmett, John Violet, Alison Y. Zhang, Nicola Jane Lawrence, Martin R. Stockler, Roslyn J. Francis, Amir Iravani, Scott Williams, Arun Azad, Andrew Martin, Margaret McJannett, Ian D. Davis

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

    Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer by Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calven Wong, Pan Du, Shidong Jia, Siddhartha Yadav, Lisa G. Horvath, Kate Mahon, Edmond M. Kwan, Heidi Fettke, Jianjun Yu, Arun Azad

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

    Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients by Nada Lallous, Stanislav Volik, Shannon Awrey, Eric Leblanc, Ronnie Tse, Josef Murillo, Kriti Singh, Arun Azad, Alexander W. Wyatt, Stéphane LeBihan, Kim N., Martin Gleave, Paul S. Rennie, Colin C. Collins, Artem Cherkasov

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup>Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol)

    UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup>Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol)... by Nattakorn Dhiantravan, Louise Emmett, Anthony M. Joshua, David A. Pattison, Roslyn J. Francis, Scott Williams, Shahneen Sandhu, Ian D. Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G. Murphy, Michael S. Hofman, Arun Azad

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

    A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prosta... by Neeraj Agarwal, Arun Azad, Joan Carles, Simon Chowdhury, Bradley A. McGregor, Axel S. Merseburger, Stéphane Oudard, Fred Saad, Andrey Soares, Fawzi Benzaghou, Yannick Kerloëguen, Akiko Kimura, Nehal Mohamed, Ashok Panneerselvam, Fong Wang, Sumanta K. Pal

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: